

> d his

(FILE 'HOME' ENTERED AT 17:49:31 ON 31 AUG 2006)

FILE 'REGISTRY' ENTERED AT 17:49:38 ON 31 AUG 2006

L1 1 S IMIQUIMOD/CN  
SEL L1

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 17:50:42 ON 31 AUG 2006  
SEA (E1-E5) AND (PHOTODAMAGE OR WRINKLE OR SUNBURN OR SCAR? OR

-----  
4 FILE ADISCTI  
1 FILE ADISINSIGHT  
4 FILE ADISNEWS  
4 FILE BIOSIS  
1 FILE BIOTECHABS  
1 FILE BIOTECHDS  
3 FILE BIOTECHNO  
1 FILE CABA  
14 FILE CAPLUS  
13 FILE DDFU  
27 FILE DRUGU  
4 FILE EMBAL  
104 FILE EMBASE  
17 FILE ESBIODBASE  
14 FILE IFIPAT  
1 FILE JICST-EPLUS  
6 FILE KOSMET  
1 FILE LIFESCI  
26 FILE MEDLINE  
21 FILE PASCAL  
1 FILE PHIN  
36 FILE PROMT  
34 FILE SCISEARCH  
15 FILE TOXCENTER  
241 FILE USPATFULL  
44 FILE USPAT2  
24 FILE WPIDS  
24 FILE WPINDEX  
13 FILE EPFULL  
156 FILE PCTFULL

L2 QUE ((ALDARA/BI OR IMIQUIMOD/BI OR "R 837"/BI OR "S 26308"/BI O  
-----

FILE 'EMBASE, MEDLINE, PASCAL, PROMT, SCISEARCH' ENTERED AT 17:53:48 ON  
31 AUG 2006

L3 221 S (E1-E5) AND (PHOTODAMAGE OR WRINKLE OR SUNBURN OR SCAR? OR (F  
L4 46 S L3 NOT PY>2002  
L5 33 DUP REM L4 (13 DUPLICATES REMOVED)

FILE 'USPATFULL, PCTFULL' ENTERED AT 17:57:05 ON 31 AUG 2006

L6 397 S (E1-E5) AND (PHOTODAMAGE OR WRINKLE OR SUNBURN OR SCAR? OR (F  
L7 101 S L6 NOT PY>2003  
L8 8 S L7 AND (AGED OR AGEING)  
L9 94 S L7 AND (TOPICAL OR TRANSDERMAL)  
L10 36 S L9 AND COSMETIC

FILE 'REGISTRY' ENTERED AT 17:49:38 ON 31 AUG 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 30 AUG 2006 HIGHEST RN 905475-39-0  
DICTIONARY FILE UPDATES: 30 AUG 2006 HIGHEST RN 905475-39-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.


REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> s imiquimod/cn  
L1 1 IMIQUIMOD/CN

=> d l1

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 99011-02-6 REGISTRY  
ED Entered STN: 09 Nov 1985  
CN 1H-Imidazo[4,5-c]quinolin-4-amine, 1-(2-methylpropyl)- (9CI) (CA INDEX  
NAME)  
OTHER NAMES:  
CN Aldara  
CN Imiquimod  
CN R 837  
CN S 26308  
MF C14 H16 N4  
CI COM  
SR CA  
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO,  
CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSChem, DDFU, DRUGU, EMBASE,  
IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK\*, PATDPASPC,  
PHAR, PROMT, PROUSDDR, PS, RTECS\*, SYNTHLINE, TOXCENTER, USAN, USPAT2,  
USPATFULL  
(\*File contains numerically searchable property data)  
Other Sources: WHO



**\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\***

350 REFERENCES IN FILE CA (1907 TO DATE)  
6 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
354 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> sel l1  
E1 THROUGH E5 ASSIGNED

=> index bioscience patents  
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED  
FILE 'ENCOMPAT2' ACCESS NOT AUTHORIZED  
COST IN U.S. DOLLARS

	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	7.87	8.08

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,  
AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,  
CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,  
DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 17:50:42 ON 31 AUG 2006

92 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view  
search error messages that display as 0\* with SET DETAIL OFF.

=> s (E1-E5) and (photodamage or wrinkle or sunburn or scar? or (fine(w)lines) or  
telangectasia)

4 FILE ADISCTI  
1 FILE ADISINSIGHT  
4 FILE ADISNEWS  
4 FILE BIOSIS  
1 FILE BIOTECHABS  
1 FILE BIOTECHDS  
3 FILE BIOTECHNO  
1 FILE CABA  
14 FILE CAPLUS

20 FILES SEARCHED...

13 FILE DDFU  
27 FILE DRUGU  
4 FILE EMBAL  
104 FILE EMBASE  
17 FILE ESBIODASE

31 FILES SEARCHED...

14 FILE IFIPAT  
1 FILE JICST-EPLUS  
6 FILE KOSMET  
1 FILE LIFESCI  
26 FILE MEDLINE

45 FILES SEARCHED...

21 FILE PASCAL  
1 FILE PHIN  
36 FILE PROMT  
34 FILE SCISEARCH  
15 FILE TOXCENTER  
241 FILE USPATFULL  
44 FILE USPAT2

63 FILES SEARCHED...

24 FILE WPIDS  
24 FILE WPINDEX  
13 FILE EPFULL

73 FILES SEARCHED...

83 FILES SEARCHED...

30 FILES HAVE ONE OR MORE ANSWERS, 92 FILES SEARCHED IN STNINDEX

L2 QUE ((ALDARA/BI OR IMIQUIMOD/BI OR "R 837"/BI OR "S 26308"/BI OR 99011-02-6/BI)) AND (PHOTODAMAGE OR WRINKLE OR SUNBURN OR SCAR? OR (FINE(W) LINES) OR TELANGECTASIA)

=> file embase medline pascal prompt scisearch

COST IN U.S. DOLLARS

SINCE FILE  
ENTRY

TOTAL  
SESSION

FULL ESTIMATED COST

3.05

11.13

FILE 'EMBASE' ENTERED AT 17:53:48 ON 31 AUG 2006

Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'MEDLINE' ENTERED AT 17:53:48 ON 31 AUG 2006

FILE 'PASCAL' ENTERED AT 17:53:48 ON 31 AUG 2006

Any reproduction or dissemination in part or in full,  
by means of any process and on any support whatsoever  
is prohibited without the prior written agreement of INIST-CNRS.  
COPYRIGHT (C) 2006 INIST-CNRS. All rights reserved.

FILE 'PROMT' ENTERED AT 17:53:48 ON 31 AUG 2006

COPYRIGHT (C) 2006 Gale Group. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 17:53:48 ON 31 AUG 2006

Copyright (c) 2006 The Thomson Corporation

=> s (E1-E5) and (photodamage or wrinkle or sunburn or scar? or (fine(w)lines) or telangectasia)

L3 221 ((ALDARA/BI OR IMIQUIMOD/BI OR "R 837"/BI OR "S 26308"/BI OR 99011-02-6/BI)) AND (PHOTODAMAGE OR WRINKLE OR SUNBURN OR SCAR? OR (FINE(W) LINES) OR TELANGECTASIA)

=> s L3 not py>2002

L4 46 L3 NOT PY>2002

=> dup rem l4

PROCESSING COMPLETED FOR L4

L5 33 DUP REM L4 (13 DUPLICATES REMOVED)

=> d l5 1-33 ti

L5 ANSWER 1 OF 33 PROMT COPYRIGHT 2006 Gale Group on STN

TI Shooting down keloids and hypertrophic scars : Therapy supported by research differs depending on disease type.

L5 ANSWER 2 OF 33 PROMT COPYRIGHT 2006 Gale Group on STN

TI CO2 excision, imiquimod drop keloid recurrence : Combination treatment doesn't cure keloids but does help in managing recurrent lesions.

L5 ANSWER 3 OF 33 PROMT COPYRIGHT 2006 Gale Group on STN

TI Imiquimod vs. interferon: cream matches injection in terms of eliminating keloid recurrence while showing no adverse events. (Dermatologic surgery).

L5 ANSWER 4 OF 33 PROMT COPYRIGHT 2006 Gale Group on STN

TI Use a variety of tools to weed out skin cancers. (Treating Multifocal Tumors).

L5 ANSWER 5 OF 33 PROMT COPYRIGHT 2006 Gale Group on STN

TI AK therapy shifts target to regions, not solo lesions: subclinical AKs can permeate entire area. ('Field Cancerization').(actinic keratosis)

L5 ANSWER 6 OF 33 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

TI Venereal warts: When to consider surgical removal.

L5 ANSWER 7 OF 33 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

TI Skin cancer and exposure to sunlight, polycyclic aromatic hydrocarbons, and arsenic.

L5 ANSWER 8 OF 33 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN DUPLICATE 1

TI Squamous cell carcinoma in situ of the penis successfully treated with imiquimod 5% cream.

L5 ANSWER 9 OF 33 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN

TI Successful treatment of chronic discoid lupus erythematosus of the scalp with imiquimod

L5 ANSWER 10 OF 33 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN

TI CO2 laser surgery for extensive, cauliflower-like anogenital condylomata acuminata: Retrospective long-term study on 19 HIV-positive and 45 HIV-negative men

L5 ANSWER 11 OF 33 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN

TI Pilot study of the effect of postoperative imiquimod 5% cream on the recurrence rate of excised keloids

L5 ANSWER 12 OF 33 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN DUPLICATE 2

TI Safety studies of topical imiquimod 5% cream on normal skin exposed to ultraviolet radiation.

L5 ANSWER 13 OF 33 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN DUPLICATE 3

TI Experimental nonsurgical tattoo removal in a guinea pig model with topical imiquimod and tretinoin.

L5 ANSWER 14 OF 33 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

TI Managing solar keratoses.

L5 ANSWER 15 OF 33 PASCAL COPYRIGHT 2006 INIST-CNRS. ALL RIGHTS RESERVED. on STN

TIEN Pilot study of the effect of postoperative imiquimod 5% cream on the recurrence rate of excised keloids  
Imiquimod: Case reports of early clinical experience in various conditions

L5 ANSWER 16 OF 33 PROMT COPYRIGHT 2006 Gale Group on STN

TI TOPICAL CREAM FOR SKIN CANCER: NEW TRIAL RESULTS PRESENTED AT 8TH WORLD CONGRESS ON CANCERS OF THE SKIN.

L5 ANSWER 17 OF 33 PROMT COPYRIGHT 2006 Gale Group on STN

TI STIs: options for treatment. (sexually transmitted infections) (Statistical Data Included)

L5 ANSWER 18 OF 33 PROMT COPYRIGHT 2006 Gale Group on STN

TI Catching crappies as a tribute to a buddy. (C) (Sports) (Weekend Athlete) (Outdoors)

L5 ANSWER 19 OF 33 PROMT COPYRIGHT 2006 Gale Group on STN

TI Local Immunomodulation in Skin Tumors.

L5 ANSWER 20 OF 33 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

TI Emerging therapies for human papillomavirus infection.

L5 ANSWER 21 OF 33 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

TI Pruritus ani: Some answers for that maddening itch!.

L5 ANSWER 22 OF 33 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

TI Warts and all a guide to diagnosis and treatment.

L5 ANSWER 23 OF 33 PROMT COPYRIGHT 2006 Gale Group on STN

TI KPR. (Brief Article)

L5 ANSWER 24 OF 33 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

TI Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum.

L5 ANSWER 25 OF 33 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

TI Recent advances. Dermatology.

L5 ANSWER 26 OF 33 PROMT COPYRIGHT 2006 Gale Group on STN

TI KPR  
Company profile

L5 ANSWER 27 OF 33 PROMT COPYRIGHT 2006 Gale Group on STN

TI Aldara Cream Stimulates Body's Natural Defenses to Clear Genital Warts Infection, New Research Shows

L5 ANSWER 28 OF 33 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

TI [Modern wart therapy].  
MODERNE WARZENTHERAPIE.

L5 ANSWER 29 OF 33 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

TI Cytokine induction and modifying the immune response to human papilloma virus with imiquimod. DUPLICATE 4

L5 ANSWER 30 OF 33 MEDLINE on STN

TI Immune response modification: imiquimod.

L5 ANSWER 31 OF 33 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

DUPLICATE 5

TI Immune response modification: Imiquimod.  
L5 ANSWER 32 OF 33 PROMT COPYRIGHT 2006 Gale Group on STN  
TI Categorical Listing of Suppliers.  
L5 ANSWER 33 OF 33 PROMT COPYRIGHT 2006 Gale Group on STN  
TI Podophyllotoxin Is Mainstay of Condyloma Acuminata Treatment

=> d l5 1 2 3 9 12 13 14 15 30 31 ti abs bib

L5 ANSWER 1 OF 33 PROMT COPYRIGHT 2006 Gale Group on STN  
TI Shooting down keloids and hypertrophic scars : Therapy supported  
by research differs depending on disease type.  
AB New Orleans -- In an attempt to subdue and prevent recurrence of keloids  
and hypertrophic scars, dermatologists should take a rationale  
approach and realize that while treatment may be similar for both lesions,  
research-supported therapy actually differs depending on type, according  
to Hilary E. Baldwin, M.D.  
THIS IS THE FULL TEXT: COPYRIGHT 2002 Advanstar Communications, Inc.  
  
Subscription: \$75.00 per year. Published monthly. 131 West First Street,  
Duluth, MN 55082.  
AN 2002:255090 PROMT  
TI Shooting down keloids and hypertrophic scars : Therapy supported  
by research differs depending on disease type.  
AU KAPES, BETH A.  
SO Dermatology Times, (March 2002) Vol. 23, No. 3, pp. 54.  
ISSN: ISSN: 0196-6197.  
PB Advanstar Communications, Inc.  
DT Newsletter  
LA English  
WC 600  
\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 2 OF 33 PROMT COPYRIGHT 2006 Gale Group on STN  
TI CO2 excision, imiquimod drop keloid recurrence : Combination  
treatment doesn't cure keloids but does help in managing recurrent  
lesions.  
AB New Orleans -- A combination approach using deep CO2 laser excision  
followed by topical treatment with imiquimod 5 percent cream (Aldara)  
may offer successful management for recurrent keloids, Robin C. Billick,  
M.D., said at the annual meeting of the American Academy of Dermatology.  
THIS IS THE FULL TEXT: COPYRIGHT 2002 Advanstar Communications, Inc.  
  
Subscription: \$75.00 per year. Published monthly. 131 West First Street,  
Duluth, MN 55082.  
AN 2002:255083 PROMT  
TI CO2 excision, imiquimod drop keloid recurrence : Combination  
treatment doesn't cure keloids but does help in managing recurrent  
lesions.  
AU GUTTMAN, CHERYL  
SO Dermatology Times, (March 2002) Vol. 23, No. 3, pp. 48.  
ISSN: ISSN: 0196-6197.  
PB Advanstar Communications, Inc.  
DT Newsletter  
LA English  
WC 775  
\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 3 OF 33 PROMT COPYRIGHT 2006 Gale Group on STN

TI Imiquimod vs. interferon: cream matches injection in terms of eliminating keloid recurrence while showing no adverse events. (Dermatologic surgery).

AB Paris -- Imiquimod 5 percent cream (Aldara), like intralesional interferon, may prevent keloid recurrence. And although imiquimod use may necessitate longer treatment--up to eight weeks compared to two injections of interferon--the drug is without adverse systemic reactions, Ivonne Arellano, M.D., said at the World Congress of Dermatology.

THIS IS THE FULL TEXT: COPYRIGHT 2002 Advanstar Communications, Inc.

Subscription: \$75.00 per year. Published monthly. 131 West First Street, Duluth, MN 55082.

AN 2003:145738 PROMT

TI Imiquimod vs. interferon: cream matches injection in terms of eliminating keloid recurrence while showing no adverse events. (Dermatologic surgery).

AU Clark, Jennifer

SO Dermatology Times, (Dec 2002) Vol. 23, No. 12, pp. 15.

ISSN: ISSN: 0196-6197.

PB Advanstar Communications, Inc.

DT Newsletter

LA English

WC 719

\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L5 ANSWER 9 OF 33 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN

TI Successful treatment of chronic discoid lupus erythematosus of the scalp with imiquimod

AN 2003:6957 SCISEARCH

GA The Genuine Article (R) Number: 623KK

TI Successful treatment of chronic discoid lupus erythematosus of the scalp with imiquimod

AU Gerdson R (Reprint); Wenzel J; Uerlich M; Bieber T; Petrow W

CS Dermatol Klin, Sigmund Freud Str 25, D-53105 Bonn, Germany (Reprint); Univ Bonn, Dept Dermatol, D-5300 Bonn, Germany

CYA Germany

SO DERMATOLOGY, (2002) Vol. 205, No. 4, pp. 416-418.

ISSN: 1018-8665.

PB KARGER, ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND.

DT Letter; Journal

LA English

REC Reference Count: 16

ED Entered STN: 10 Jan 2003

Last Updated on STN: 10 Jan 2003

L5 ANSWER 12 OF 33 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN DUPLICATE 2

TI Safety studies of topical imiquimod 5% cream on normal skin exposed to ultraviolet radiation.

AB Background: Imiquimod 5% topical cream is an immune response modifier that induces interferon alpha and interleukin-12, and exhibits antiviral and tumor-inhibiting properties. It is currently available for treatment of genital and perianal warts. Three randomized, open-label or assessor-blinded, placebo-controlled studies were carried out to assess its safety on normal white skin exposed to ultraviolet radiation (UVR). Methods: Healthy white volunteer adult subjects between the ages of 18 and 60 years with skin types I, II or III (Fitzpatrick Scale, US Federal Register 43:38260, 1978) were invited to participate. Imiquimod 5% cream (each dose .apprx.0.1-0.2 ml) was compared with placebo cream.



Two preliminary studies assessed the potential photosensitizing properties of the drug, and the third study added measurement of sunburn cell counts (SBC) and deoxyribonucleic acid (DNA) pyrimidine dimer (PD) formation. The three studies were: a 6-week standard photocontact allergenicity bioassay; a 4-day standard phototoxicity bioassay; and a 4-week photodamage study using biopsy sample analyses to determine SBC or PD frequency. Results: Imiquimod had no detectable potential for inducing either photocontact allergy (n=115) or phototoxicity (n=20). The final study further assessing photodamage potential of imiquimod included 44 subjects. There were no significant differences between imiquimod vs. the control (no drug+UVB) for SBC counts (mean 0.88 vs. 0.93), or PD frequency (mean 60.86 vs. 70.03). Conclusions: Results from the two preliminary safety studies suggest that imiquimod 5% cream does not possess a detectable photosensitizing potential in humans. Furthermore, topical imiquimod did not enhance UVR-induced damage to epidermal cells or DNA. .COPYRGT. 2002 Published by Elsevier Science Ireland Ltd.

AN 2002288272 EMBASE

TI Safety studies of topical imiquimod 5% cream on normal skin exposed to ultraviolet radiation.

AU Kaidbey K.; Owens M.; Liberda M.; Smith M.

CS K. Kaidbey, KGL, Inc. (Ivy Laboratories), University City Science Center, 3401 Market Street, Philadelphia, PA 19104-3355, United States. marijane@bellatlantic.net

SO Toxicology, (2 Sep 2002) Vol. 178, No. 2, pp. 175-182. . Refs: 17

ISSN: 0300-483X CODEN: TXCYAC

PUI S 0300-483X(02)00320-7

CY Ireland

DT Journal; Article

FS 013 Dermatology and Venereology

037 Drug Literature Index

LA English

SL English

ED Entered STN: 29 Aug 2002

Last Updated on STN: 29 Aug 2002

L5 ANSWER 13 OF 33 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN DUPLICATE 3

TI Experimental nonsurgical tattoo removal in a guinea pig model with topical imiquimod and tretinoin.

AB BACKGROUND. Tattoo removal is a common request in dermatologic surgery practices. Conventional tattoo removal modalities consist of mechanical, chemical, and thermal methods, but these interventions may result in undesirable dermal damage, disfiguring scars, and pigmentary changes. OBJECTIVE. To evaluate the efficacy of topical imiquimod and tretinoin for the removal of tattoos in a guinea pig model. METHODS. Five albino guinea pigs (A-E) were tattooed with black, red, green, and yellow. Beginning 6 hours after tattooing, A received no treatment, B was treated with petrolatum, C had imiquimod cream alternating with tretinoin gel, D had imiquimod cream alone, and E received tretinoin gel alone. The animals were treated for 7 days. Biopsies of the tattoos were taken at 6 hours, 7 days, and 28 days. RESULTS. Control guinea pig B had normal-appearing tattoos with consistent histopathology on day 28. Guinea pig D, treated with imiquimod cream clinically, had no visible tattoo, consistent with greatly diminished or no dye evident on histopathology. Guinea pig E, treated with tretinoin gel, and guinea pig C, treated with combination tretinoin gel and imiquimod cream, had faded tattoos and moderate clearance of pigment on histopathology. CONCLUSION. In the guinea pig, the use of imiquimod was successful as a nonsurgical method of acute-phase tattoo removal, but was associated with fibrosis and the loss of dermal appendages.

AN 2002043673 EMBASE

TI Experimental nonsurgical tattoo removal in a guinea pig model with topical  
 imiquimod and tretinoin.  
 AU Solis R.R.; Diven D.G.; Colome-Grimmer M.I.; Snyder IV N.; Wagner Jr.  
 R.F.; Christian M.M.  
 CS Dr. R.F. Wagner Jr., University of Texas Medical Branch, Department of  
 Dermatology, Galveston, TX 77555-0783, United States  
 SO Dermatologic Surgery, (2002) Vol. 28, No. 1, pp. 83-87. .  
 Refs: 15  
 ISSN: 1076-0512 CODEN: DESUFE  
 CY United States  
 DT Journal; Article  
 FS 013 Dermatology and Venereology  
 037 Drug Literature Index  
 LA English  
 SL English  
 ED Entered STN: 14 Feb 2002  
 Last Updated on STN: 14 Feb 2002

L5 ANSWER 14 OF 33 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights  
 reserved on STN  
 TI Managing solar keratoses.  
 AB Solar keratoses (actinic keratoses) are common, often multiple, epidermal  
 lesions found mainly on the sun-exposed skin of fair-skinned middle-aged  
 and older people. They may transform into non-melanoma skin cancers,  
 particularly squamous cell carcinoma. Here, we review the prevention and  
 treatment of solar keratoses.  
 AN 2002197041 EMBASE  
 TI Managing solar keratoses.  
 SO Drug and Therapeutics Bulletin, (2002) Vol. 40, No. 5, pp. 33-35. .  
 Refs: 29  
 ISSN: 0012-6543 CODEN: DRTBAE  
 CY United Kingdom  
 DT Journal; Article  
 FS 013 Dermatology and Venereology  
 016 Cancer  
 030 Pharmacology  
 036 Health Policy, Economics and Management  
 037 Drug Literature Index  
 038 Adverse Reactions Titles  
 LA English  
 SL English  
 ED Entered STN: 20 Jun 2002  
 Last Updated on STN: 20 Jun 2002

L5 ANSWER 15 OF 33 PASCAL COPYRIGHT 2006 INIST-CNRS. ALL RIGHTS RESERVED.  
 on STN  
 TIEN Pilot study of the effect of postoperative imiquimod 5% cream  
 on the recurrence rate of excised keloids  
 Imiquimod: Case reports of early clinical experience in various  
 conditions  
 AN 2003-0019569 PASCAL  
 CP Copyright .COPYRGT. 2003 INIST-CNRS. All rights reserved.  
 AB New adjunctive treatments are needed to reduce the high recurrence rates  
 (50%) of excised keloids. Interferon alfa injections have been shown to  
 decrease the size of stable keloids. This study examined the effects of  
 postoperative imiquimod 5% cream on the recurrence of 13  
 keloids excised surgically from 12 patients. Starting on the night of  
 surgery, imiquimod 5% cream was applied for 8 weeks. Patients  
 were examined at weeks 4, 8, 16, and 24 for local erythema, edema,  
 erosions, pigment alteration, and/or recurrence of keloids. Of the 11  
 keloids evaluated at 24 weeks, none (0%) recurred. Incidences of  
 hyperpigmentation were 63.6%. Two cases of mild irritation and  
 superficial erosion cleared with temporary discontinuation of  
 imiquimod. Both patients completed the 8 weeks of topical therapy

and the final 24-week assessment. At 24 weeks the recurrence rate of excised keloids treated with postoperative imiquimod 5% cream was lower than recurrence rates previously reported in the literature.

CP Copyright .COPYRGT. 2003 INIST-CNRS. All rights reserved.

TIEN Pilot study of the effect of postoperative imiquimod 5% cream on the recurrence rate of excised keloids

Imiquimod: Case reports of early clinical experience in various conditions

AU BERMAN Brian; KAUFMAN Joely  
DAHL Mark V. (ed.)

CS Department of Dermatology and Cutaneous Surgery, University of Miami School of Medicine., United States  
Department of Dermatology, Mayo Medical School and Mayo Clinic  
Scottsdale, Scottsdale, Arizona, United States

SO Journal of the American Academy of Dermatology, (2002), 47(4, SUP), S209-S211, 17 refs.  
ISSN: 0190-9622 CODEN: JAADDB

DT Journal

BL Analytic

CY United States

LA English

AV INIST-18387, 354000109313020010

L5 ANSWER 30 OF 33 MEDLINE on STN

TI Immune response modification: imiquimod.

AB Imiquimod is 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine and has a molecular formula of C<sub>14</sub>H<sub>16</sub>N<sub>4</sub>. It was discovered by researchers at 3M Pharmaceuticals (St Paul, MN, USA) and is the newest in a class of drugs known as immune response modifiers. Imiquimod 5% cream has been formulated for the treatment of external genital and perianal warts (condylomata acuminata) in male and female patients. Each gram of 5% cream contains 50 mg of imiquimod. In preclinical studies, imiquimod induced the production of cytokines, the principal one for antiviral activity being interferon-alpha. Imiquimod does not induce direct antiviral activity, nor does it cause direct, non-specific cytolytic destruction. Preclinical studies suggest that its antiviral action results from in vivo cytokine-induced activation of the immune system. A double-blind, placebo-controlled study designed to evaluate this hypothesis has been previously presented. The results of the study showed that wart regression after treatment with imiquimod is strongly correlated with a decrease in virally infected cells and with increases in the expression of a spectrum of cytokines. This supports the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction of human papillomavirus load and wart regression, without evidence of scarring.

AN 1999058235 MEDLINE

DN PubMed ID: 9842095

TI Immune response modification: imiquimod.

AU Tying S

CS University of Texas Medical Branch, Galveston 77555, USA.

SO The Australasian journal of dermatology, (1998 Nov) Vol. 39 Suppl 1, pp. S11-3.  
Journal code: 0135232. ISSN: 0004-8380.

CY Australia

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals; AIDS

EM 199812

ED Entered STN: 15 Jan 1999  
Last Updated on STN: 15 Jan 1999  
Entered Medline: 22 Dec 1998

L5 ANSWER 31 OF 33 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights

reserved on STN

DUPLICATE 5

TI Immune response modification: Imiquimod.  
AB Imiquimod is 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine and has a molecular formula of C<sub>14</sub>H<sub>16</sub>N<sub>4</sub>. It was discovered by researchers at 3M Pharmaceuticals (St Paul, MN, USA) and is the newest in a class of drugs known as immune response modifiers. Imiquimod 5% cream has been formulated for the treatment of external genital and perianal warts (condylomata acuminata) in male and female patients. Each gram of 5% cream contains 50 mg of imiquimod. In preclinical studies, imiquimod induced the production of cytokines, the principal one for antiviral activity being interferon- $\alpha$ . Imiquimod does not induce direct antiviral activity, nor does it cause direct, non-specific cytolytic destruction. Preclinical studies suggest that its antiviral action results from in vivo cytokine-induced activation of the immune system. A double-blind, placebo-controlled study designed to evaluate this hypothesis has been previously presented. The results of the study showed that wart regression after treatment with imiquimod is strongly correlated with a decrease in virally infected cells and with increases in the expression of a spectrum of cytokines. This supports the hypothesis that stimulation of local cytokines by imiquimod leads to a reduction of human papillomavirus load and wart regression, without evidence of scarring.  
AN 1998401640 EMBASE  
TI Immune response modification: Imiquimod.  
AU Tyring S.  
CS Dr. S. Tyring, University of Texas Medical Branch, Route 1070, Galveston, TX 77555, United States  
SO Australasian Journal of Dermatology, (1998) Vol. 39, No. SUPPL. 1, pp. S11-S13. .  
Refs: 10  
ISSN: 0004-8380 CODEN: AJDEBP  
CY Australia  
DT Journal; Conference Article  
FS 004 Microbiology  
026 Immunology, Serology and Transplantation  
030 Pharmacology  
037 Drug Literature Index  
038 Adverse Reactions Titles  
LA English  
SL English  
ED Entered STN: 17 Dec 1998  
Last Updated on STN: 17 Dec 1998

=> file uspatfull pctfull

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

37.25

48.38

FILE 'USPATFULL' ENTERED AT 17:57:05 ON 31 AUG 2006

CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PCTFULL' ENTERED AT 17:57:05 ON 31 AUG 2006

COPYRIGHT (C) 2006 Univentio

=> s (E1-E5) and (photodamage or wrinkle or sunburn or scar? or (fine(w)lines) or telangectasia)

L6 397 ((ALDARA/BI OR IMIQUIMOD/BI OR "R 837"/BI OR "S 26308"/BI OR 99011-02-6/BI)) AND (PHOTODAMAGE OR WRINKLE OR SUNBURN OR SCAR? OR (FINE(W) LINES) OR TELANGECTASIA)

=> s L6 not py>2003

L7 101 L6 NOT PY>2003

=> s L7 and (aged or ageing)  
L8 8 L7 AND (AGED OR AGEING)

=> d l8 1-8 ti

L8 ANSWER 1 OF 8 USPATFULL on STN  
TI Pharmaceutical compositions and methods for managing connective tissue ailments

L8 ANSWER 2 OF 8 USPATFULL on STN  
TI 12 human secreted proteins

L8 ANSWER 3 OF 8 USPATFULL on STN  
TI Methods and compositions for treating dermatological disorders with *Morinda citrifolia*

L8 ANSWER 4 OF 8 USPATFULL on STN  
TI 12 human secreted proteins

L8 ANSWER 5 OF 8 USPATFULL on STN  
TI Pharmaceutical compositions and methods for managing dermatological conditions

L8 ANSWER 6 OF 8 USPATFULL on STN  
TI 32 human secreted proteins

L8 ANSWER 7 OF 8 PCTFULL COPYRIGHT 2006 Univentio on STN  
TIEN DEHYDROASCORBIC ACID FORMULATIONS AND USES THEREOF  
TIFR FORMULATIONS D'ACIDE DEHYDROASCRBIQUE ET LEURS UTILISATIONS

L8 ANSWER 8 OF 8 PCTFULL COPYRIGHT 2006 Univentio on STN  
TIEN 12 HUMAN SECRETED PROTEINS  
TIFR 12 PROTEINES HUMAINES SECRETEES

=> s l7 and (topical or transdermal)  
L9 94 L7 AND (TOPICAL OR TRANSDERMAL)

=> s l9 and cosmetic  
L10 36 L9 AND COSMETIC

=> d l10 1-36 ti

L10 ANSWER 1 OF 36 USPATFULL on STN  
TI N-acetyl cysteine and its topical use

L10 ANSWER 2 OF 36 USPATFULL on STN  
TI 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use

L10 ANSWER 3 OF 36 USPATFULL on STN  
TI Pharmaceutical compositions and methods for managing connective tissue ailments

L10 ANSWER 4 OF 36 USPATFULL on STN  
TI 12 human secreted proteins

L10 ANSWER 5 OF 36 USPATFULL on STN  
TI Diindolylmethane for the treatment of HPV infection

L10 ANSWER 6 OF 36 USPATFULL on STN  
TI Methods and compositions for treating dermatological disorders with *Morinda citrifolia*

L10 ANSWER 7 OF 36 USPATFULL on STN  
 TI Topical pharmaceutical composition for the treatment of inflammatory dermatoses

L10 ANSWER 8 OF 36 USPATFULL on STN  
 TI Topical pharmaceutical composition for the treatment of warts

L10 ANSWER 9 OF 36 USPATFULL on STN  
 TI Topical pharmaceutical composition to treat hyperpigmentation of the skin

L10 ANSWER 10 OF 36 USPATFULL on STN  
 TI 12 human secreted proteins

L10 ANSWER 11 OF 36 USPATFULL on STN  
 TI Selective enzyme treatment of skin conditions

L10 ANSWER 12 OF 36 USPATFULL on STN  
 TI Pharmaceutical compositions and methods for managing dermatological conditions

L10 ANSWER 13 OF 36 USPATFULL on STN  
 TI Thiazolyl urea compounds and methods of uses

L10 ANSWER 14 OF 36 USPATFULL on STN  
 TI Urea compounds and methods of uses

L10 ANSWER 15 OF 36 USPATFULL on STN  
 TI 32 human secreted proteins

L10 ANSWER 16 OF 36 USPATFULL on STN  
 TI METHODS AND APPARATUS FOR DRUG DELIVERY INVOLVING PHASE CHANGING FORMULATIONS

L10 ANSWER 17 OF 36 USPATFULL on STN  
 TI Oligosaccharide aldonic acids and their topical use

L10 ANSWER 18 OF 36 USPATFULL on STN  
 TI Multi-purpose drug and heat therapy treatment system

L10 ANSWER 19 OF 36 PCTFULL COPYRIGHT 2006 Univentio on STN  
 TIEN USE OF TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING AN ACTIVE AGENT AND PERMEATION-ENHANCING BASE FOR THE MANUFACTURE OF A MEDICAMENT TO TREAT VARIOUS FORMS OF INFLAMMATORY DERMATOSIS  
 TIFR UTILISATION DE COMPOSITIONS PHARMACEUTIQUES TOPIQUES CONTENANT UN AGENT ACTIF ET UNE BASE A AMELIORATION DE PERMEABILITE POUR LA FABRICATION D'UN MEDICAMENT AFIN DE TRAITER DIFFERENTES FORMES DE DERMATOSES INFLAMMATOIRES

L10 ANSWER 20 OF 36 PCTFULL COPYRIGHT 2006 Univentio on STN  
 TIEN TOPICAL PHARMACEUTICAL COMPOSITION COMPRISING SKIN PENETRATION ENHANCERS FOR THE TREATMENT OF WARTS  
 TIFR COMPOSITION PHARMACEUTIQUE TOPIQUE RENFERMANT DES STIMULATEURS DE PERMEATION CUTANEE POUR LE TRAITEMENT DES VERRUES

L10 ANSWER 21 OF 36 PCTFULL COPYRIGHT 2006 Univentio on STN  
 TIEN TOPICAL ADMINISTRATION OF PHARMACOLOGICALLY ACTIVE BASES IN THE TREATMENT OF WARTS  
 TIFR ADMINISTRATION TOPIQUE DE BASES PHARMACEUTIQUEMENT ACTIVES DANS LE TRAITEMENT DES VERRUES

L10 ANSWER 22 OF 36 PCTFULL COPYRIGHT 2006 Univentio on STN  
 TIEN TOPICAL PHARMACEUTICAL COMPOSITION TO TREAT HYPERPIGMENTATION OF THE SKIN

TIFR COMPOSITION PHARMACEUTIQUE TOPIQUE PERMETTANT DE TRAITER UNE  
HYPER-PIGMENTATION CUTANEE

L10 ANSWER 23 OF 36 PCTFULL COPYRIGHT 2006 Univentio on STN  
TIEN 2-OXO-1,3,4-TRIHYDROQUINAZOLINYL DERIVATIVES FOR THE TREATMENT OF CELL  
PROLIFERATION-RELATED DISORDERS

TIFR DERIVES 2-OXO-1,3,4-TRIHYDROQUINAZOLINYLE UTILISES DANS LE TRAITEMENT DE  
TROUBLES ASSOCIES A LA PROLIFERATION DE CELLULES

L10 ANSWER 24 OF 36 PCTFULL COPYRIGHT 2006 Univentio on STN  
TIEN UREA COMPOSITIONS  
TIFR COMPOSITIONS D'UREE

L10 ANSWER 25 OF 36 PCTFULL COPYRIGHT 2006 Univentio on STN  
TIEN THIAZOLYL UREA COMPOUNDS FOR THE TREATMENT OF CANCER  
TIFR COMPOSES DE THIAZOLYL UREE POUR LE TRAITEMENT DU CANCER

L10 ANSWER 26 OF 36 PCTFULL COPYRIGHT 2006 Univentio on STN  
TIEN COMPOUNDS AND METHODS OF USES  
TIFR COMPOSES ET PROCEDES D'UTILISATION

L10 ANSWER 27 OF 36 PCTFULL COPYRIGHT 2006 Univentio on STN  
TIEN COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES  
TIFR COMPOSITIONS COMPRENANT DES DERIVES DE PHENYLE-GLYCINE

L10 ANSWER 28 OF 36 PCTFULL COPYRIGHT 2006 Univentio on STN  
TIEN DIINDOLYLMETHANE FOR THE TREATMENT OF HPV INFECTION  
TIFR DI-INDOLYLMETHANE POUR LE TRAITEMENT D'INFECTIONS PAR LE PAPILLOMAVIRUS  
HUMAIN

L10 ANSWER 29 OF 36 PCTFULL COPYRIGHT 2006 Univentio on STN  
TIEN USE OF ASIATIC ACID OR ASIATICOSIDE FOR TREATMENT OF CANCER  
TIFR UTILISATION D'ACIDE ASIATIQUE OU D'ASIATICOSIDE POUR LE TRAITEMENT DU  
CANCER

L10 ANSWER 30 OF 36 PCTFULL COPYRIGHT 2006 Univentio on STN  
TIEN UREA COMPOUNDS AND METHODS OF USES  
TIFR COMPOSES D'UREE ET LEURS PROCEDES D'UTILISATION

L10 ANSWER 31 OF 36 PCTFULL COPYRIGHT 2006 Univentio on STN  
TIEN MULTI-PURPOSE DRUG AND HEAT THERAPY TREATMENT SYSTEM  
TIFR MEDICAMENT POLYVALENT ET SYSTEME DE THERMOTHERAPIE

L10 ANSWER 32 OF 36 PCTFULL COPYRIGHT 2006 Univentio on STN  
TIEN DRUG DELIVERY OF PHASE CHANGING FORMULATION  
TIFR APPORT DE MEDICAMENTS DE PREPARATIONS A CHANGEMENT DE PHASE

L10 ANSWER 33 OF 36 PCTFULL COPYRIGHT 2006 Univentio on STN  
TIEN OLIGOSACCHARIDE ALDONIC ACIDS AND THEIR TOPICAL USE  
TIFR ACIDES ALDONIQUES OLIGOSIDES ET LEUR USAGE TOPIQUE

L10 ANSWER 34 OF 36 PCTFULL COPYRIGHT 2006 Univentio on STN  
TIEN 12 HUMAN SECRETED PROTEINS  
TIFR 12 PROTEINES HUMAINES SECRETEES

L10 ANSWER 35 OF 36 PCTFULL COPYRIGHT 2006 Univentio on STN  
TIEN A NOVEL BIOADHESIVE DRUG DELIVERY SYSTEM BASED ON LIQUID CRYSTALS  
TIFR NOUVEAU SYSTEME BIOADHESIF D'ADMINISTRATION DE MEDICAMENTS BASE SUR DES  
CRISTAUX LIQUIDES

L10 ANSWER 36 OF 36 PCTFULL COPYRIGHT 2006 Univentio on STN  
TIEN A PHARMACEUTICAL COMPOSITION FOR ADMINISTRATION OF AN ACTIVE SUBSTANCE  
TO OR THROUGH A SKIN OR MUCOSAL SURFACE  
TIFR COMPOSITION PHARMACEUTIQUE POUR L'ADMINISTRATION D'UN PRINCIPE ACTIF SUR

OU AU TRAVERS D'UNE SURFACE CUTANEE OU MUQUEUSE

=> d 110 4 7 9 11 12 19 ti abs bib

L10 ANSWER 4 OF 36 USPATFULL on STN

TI 12 human secreted proteins

AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:187895 USPATFULL

TI 12 human secreted proteins

IN Ni, Jian, Germantown, MD, UNITED STATES

Young, Paul E., Gaithersburg, MD, UNITED STATES

Kenny, Joseph J., Damascus, MD, UNITED STATES

Olsen, Henrik S., Gaithersburg, MD, UNITED STATES

Moore, Paul A., Germantown, MD, UNITED STATES

Wei, Ying-Fei, Berkeley, CA, UNITED STATES

Greene, John M., Gaithersburg, MD, UNITED STATES

Ruben, Steven M., Olney, MD, UNITED STATES

PI US 2003129685 A1 20030710

AI US 2001-836353 A1 20010418 (9)

RLI Continuation-in-part of Ser. No. WO 1999-US25031, filed on 27 Oct 1999, UNKNOWN

PRAI US 1998-105971P 19981028 (60)

US 2000-198407P 20000419 (60)

DT Utility

FS APPLICATION

LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

CLMN Number of Claims: 23

ECL Exemplary Claim: 1

DRWN 59 Drawing Page(s)

LN.CNT 31945

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 7 OF 36 USPATFULL on STN

TI Topical pharmaceutical composition for the treatment of inflammatory dermatoses

AB Provided is a topical pharmaceutical composition for the treatment of inflammatory dermatoses, including acne vulgaris, together with methods for its use. The composition and methods involve the topical use of an active agent effective in the treatment of inflammatory dermatoses plus a permeation-enhancing base that, in one embodiment, gives the composition a pH of about 8.0 to about 13.0, preferably about 8.0 to 11.5, and most preferably about 8.5 to 10.5.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:112571 USPATFULL

TI Topical pharmaceutical composition for the treatment of inflammatory dermatoses

IN Maibach, Howard I., San Francisco, CA, UNITED STATES

Luo, Eric C., Plano, TX, UNITED STATES

Hsu, Tsung-Min, San Diego, CA, UNITED STATES

PI US 2003077301 A1 20030424

AI US 2002-177250 A1 20020621 (10)

RLI Continuation-in-part of Ser. No. US 2001-972008, filed on 4 Oct 2001, PENDING Continuation-in-part of Ser. No. US 2000-738410, filed on 14 Dec 2000, PENDING Continuation-in-part of Ser. No. US 2000-569889, filed on



11 May 2000, PENDING Continuation-in-part of Ser. No. US 1999-465098, filed on 16 Dec 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-738395, filed on 14 Dec 2000, PENDING Continuation-in-part of Ser. No. US 2000-607892, filed on 30 Jun 2000, ABANDONED

DT Utility  
FS APPLICATION  
LREP REED & EBERLE LLP, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025  
CLMN Number of Claims: 121  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1903  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 9 OF 36 USPATFULL on STN

TI Topical pharmaceutical composition to treat hyperpigmentation of the skin  
AB Provided is a topical pharmaceutical composition for skin lightening, which is particularly useful in treating skin hyperpigmentation, together with methods for its use. The composition and methods involve the topical use of an active agent effective in the treatment of skin hyperpigmentation plus a permeation-enhancing base that, in one embodiment, gives the composition a pH of about 8.0 to about 13.0, preferably about 8.0 to 11.5, and most preferably about 8.5 to 10.5.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:105814 USPATFULL  
TI Topical pharmaceutical composition to treat hyperpigmentation of the skin  
IN Maibach, Howard I., San Francisco, CA, UNITED STATES  
Luo, Eric C., Plano, TX, UNITED STATES  
Hsu, Tsung-Min, San Diego, CA, UNITED STATES  
PI US 2003072724 A1 20030417  
AI US 2002-178082 A1 20020621 (10)  
RLI Continuation-in-part of Ser. No. US 2001-972008, filed on 4 Oct 2001, PENDING Continuation-in-part of Ser. No. US 2000-738410, filed on 14 Dec 2000, PENDING Continuation-in-part of Ser. No. US 2000-569889, filed on 11 May 2000, PENDING Continuation-in-part of Ser. No. US 1999-465098, filed on 16 Dec 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-738395, filed on 14 Dec 2000, PENDING Continuation-in-part of Ser. No. US 2000-607892, filed on 30 Jun 2000, ABANDONED

DT Utility  
FS APPLICATION  
LREP REED & EBERLE LLP, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025  
CLMN Number of Claims: 97  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1693  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 11 OF 36 USPATFULL on STN

TI Selective enzyme treatment of skin conditions  
AB A method of treating skin conditions by providing compositions containing enzymes to selectively remove specific layers of skin. The depth of skin removed (that is, vertical surface treated) is regulated by the type and concentration of enzyme or enzymes in the composition. The surface area of skin removed (that is, radial surface treated) is regulated by the area of topical application. Conditions treatable by the method include, but are not limited to, age-related conditions such as lines and wrinkles, infections, pigmentary disorders, follicular disorders such as acne, and hyperkeratotic disorders such as warts. The inventive method and composition thus achieves the specificity and efficacy of more invasive methods such as surgery, while providing a composition that may be topically applied and is easy to

use.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:37150 USPATFULL  
TI Selective enzyme treatment of skin conditions  
IN Fein, Howard, Cincinnati, OH, UNITED STATES  
PI US 2003026794 A1 20030206  
AI US 2001-919102 A1 20010731 (9)  
DT Utility  
FS APPLICATION  
LREP Beverly A. Lyman, Wood, Herron & Evans, L.L.P., 2700 Carew Tower, 441  
Vine Street, Cincinnati, OH, 45202-2917  
CLMN Number of Claims: 41  
ECL Exemplary Claim: 1  
DRWN 3 Drawing Page(s)  
LN.CNT 908

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 12 OF 36 USPATFULL on STN

TI Pharmaceutical compositions and methods for managing dermatological conditions  
AB Pharmaceutical composition including hydrogen peroxide and at least one other dermatological agent. The pharmaceutical compositions cleanse the dermatological surfaces and facilitate penetration of the at least one other dermatological for the treatment of a dermatological condition. The pharmaceutical compositions are useful in methods of treating, preventing, and managing skin conditions, scalp conditions, hair conditions, and nail conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:10246 USPATFULL  
TI Pharmaceutical compositions and methods for managing dermatological conditions  
IN Murad, Howard, Marina del Rey, CA, UNITED STATES  
PI US 2003007939 A1 20030109  
AI US 2002-77928 A1 20020220 (10)  
RLI Continuation-in-part of Ser. No. US 2001-953431, filed on 17 Sep 2001, PENDING Continuation-in-part of Ser. No. US 2001-878231, filed on 12 Jun 2001, GRANTED, Pat. No. US 6383523 Continuation of Ser. No. US 2000-549202, filed on 13 Apr 2000, GRANTED, Pat. No. US 6296880 Continuation-in-part of Ser. No. US 1999-330127, filed on 11 Jun 1999, GRANTED, Pat. No. US 6071541  
PRAI US 1998-94775P 19980731 (60)  
DT Utility  
FS APPLICATION  
LREP PENNIE & EDMONDS LLP, 1667 K STREET NW, SUITE 1000, WASHINGTON, DC, 20006  
CLMN Number of Claims: 31  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 2119

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 19 OF 36 PCTFULL COPYRIGHT 2006 Univentio on STN

TIE USE OF TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING AN ACTIVE AGENT AND PERMEATION-ENHANCING BASE FOR THE MANUFACTURE OF A MEDICAMENT TO TREAT VARIOUS FORMS OF INFLAMMATORY DERMATOSIS  
TIFR UTILISATION DE COMPOSITIONS PHARMACEUTIQUES TOPIQUES CONTENANT UN AGENT ACTIF ET UNE BASE A AMELIORATION DE PERMEABILITE POUR LA FABRICATION D'UN MEDICAMENT AFIN DE TRAITER DIFFERENTES FORMES DE DERMATOSES INFLAMMATOIRES  
ABEN Provided is a topical pharmaceutical composition for the treatment of inflammatory dermatoses, including acne vulgaris, together with methods for its use. The composition and methods involve the

topical use of an active agent effective in the treatment of inflammatory dermatoses plus a permeation-enhancing base that, in one embodiment, gives the composition a pH of about 8.0 to about 13.0, preferably about 8.0 to 11.5, and most preferably about 8.5 to 10.5.

ABFR L'invention porte sur une composition pharmaceutique topique pour le traitement de dermatoses inflammatoires, y compris l'acne, ainsi que sur des procedes d'utilisation. Cette composition et ces procedes concernent l'utilisation topique d'un agent actif efficace dans la traitement de dermatoses inflammatoires, ainsi qu'une base ameliorant la permeabilite qui, dans un mode de realisation, fournit a la composition un pH compris entre environ 8.0 et 13.0, de preference entre environ 8.0 et 11.5, et idealement entre environ 8.5 et 10.5.

AN 2004000360 PCTFULL ED 20040115 EW 200401

TIEN USE OF TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING AN ACTIVE AGENT AND PERMEATION-ENHANCING BASE FOR THE MANUFACTURE OF A MEDICAMENT TO TREAT VARIOUS FORMS OF INFLAMMATORY DERMATOSIS

TIFR UTILISATION DE COMPOSITIONS PHARMACEUTIQUES TOPIQUES CONTENANT UN AGENT ACTIF ET UNE BASE A AMELIORATION DE PERMEABILITE POUR LA FABRICATION D'UN MEDICAMENT AFIN DE TRAITER DIFFERENTES FORMES DE DERMATOSES INFLAMMATOIRES

IN MAIBACH, Howard, I., 2745 Larkin Street, San Francisco, CA 94109, US; LUO, Eric, C., 6833 Saint Lawrence Street, Plano, TX 75024, US; HSU, Tsung-Min, 11745 Stoney Peak Drive Apt. #222, San Diego, CA 92128, US

PA DERMATRENDS, INC., 10130 Sorrento Valley Road, Suite A, San Diego, CA 92121, US [US, US]

AG EBERLE, Shelley, P., Reed & Eberle LLP, 800 Menlo Avenue, Suite 210, Menlo Park, CA 94025, US

LAF English

LA English

DT Patent

PI WO 2004000360 A1 20031231

DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW

RW (EAPO): AM AZ BY KG KZ MD RU TJ TM

RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AI WO 2003-US19805 A 20030620

PRAI US 2002-10/177,250 20020621

=> d his

(FILE 'HOME' ENTERED AT 17:49:31 ON 31 AUG 2006)

FILE 'REGISTRY' ENTERED AT 17:49:38 ON 31 AUG 2006

L1 1 S IMIQUIMOD/CN  
SEL L1

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 17:50:42 ON 31 AUG 2006  
SEA (E1-E5) AND (PHOTODAMAGE OR WRINKLE OR SUNBURN OR SCAR? OR

-----  
4 FILE ADISCTI  
1 FILE ADISINSIGHT  
4 FILE ADISNEWS  
4 FILE BIOSIS

1 FILE BIOTECHABS  
 1 FILE BIOTECHDS  
 3 FILE BIOTECHNO  
 1 FILE CABA  
 14 FILE CAPLUS  
 13 FILE DDFU  
 27 FILE DRUGU  
 4 FILE EMBAL  
 104 FILE EMBASE  
 17 FILE ESBIODBASE  
 14 FILE IFIPAT  
 1 FILE JICST-EPLUS  
 6 FILE KOSMET  
 1 FILE LIFESCI  
 26 FILE MEDLINE  
 21 FILE PASCAL  
 1 FILE PHIN  
 36 FILE PROMT  
 34 FILE SCISEARCH  
 15 FILE TOXCENTER  
 241 FILE USPATFULL  
 44 FILE USPAT2  
 24 FILE WPIDS  
 24 FILE WPINDEX  
 13 FILE EPFULL  
 156 FILE PCTFULL

L2 QUE ((ALDARA/BI OR IMIQUIMOD/BI OR "R 837"/BI OR "S 26308"/BI O  
 -----

FILE 'EMBASE, MEDLINE, PASCAL, PROMT, SCISEARCH' ENTERED AT 17:53:48 ON  
 31 AUG 2006

L3 221 S (E1-E5) AND (PHOTODAMAGE OR WRINKLE OR SUNBURN OR SCAR? OR (F  
 L4 46 S L3 NOT PY>2002  
 L5 33 DUP REM L4 (13 DUPLICATES REMOVED)

FILE 'USPATFULL, PCTFULL' ENTERED AT 17:57:05 ON 31 AUG 2006

L6 397 S (E1-E5) AND (PHOTODAMAGE OR WRINKLE OR SUNBURN OR SCAR? OR (F  
 L7 101 S L6 NOT PY>2003  
 L8 8 S L7 AND (AGED OR AGEING)  
 L9 94 S L7 AND (TOPICAL OR TRANSDERMAL)  
 L10 36 S L9 AND COSMETIC